Contents 3 min read
Claim and source comparison
Compared accessed methods/results excerpts from Yoshino 2021; abstracts of Irie 2020, Mills 2016 and Yang 2026; and the FDA’s general supplement guidance. This limited reading is not an independent medical or complete clinical review.
· Bounded source comparison; not a complete clinical review or independent medical endorsement.
Human randomized controlled trial
Yoshino et al. (2021) studied 250 mg/day NMN or placebo for 10 weeks in 25 postmenopausal women with prediabetes and overweight/obesity. Muscle insulin sensitivity improved; muscle NAD+ content did not increase and many other metabolic measures were unchanged. Cognition, dementia prevention and lifespan were not evaluated.
Muscle insulin sensitivity in a selected group of women with prediabetes is not general metabolic improvement in healthy people or increased brain NAD+. Tissue measurements, cognition, dementia prevention and lifespan are distinct outcomes.
Source 1 · Full text read
Human pharmacokinetic study
Irie et al. (2020) studied single doses of 100, 250 and 500 mg NMN in 10 healthy men over 5 hours. Nicotinamide metabolites rose; this trial did not demonstrate blood NAD+ increases or long-term anti-aging effects.
This single-arm, nonrandomized experiment followed 10 men for 5 hours. Increased metabolites do not establish NMN plasma half-life or long-term safety; increased blood NAD+, slower aging and personal doses cannot be inferred.
Source 2 · Abstract read
Animal study
Mills et al. (2016) reported improvements in selected age-associated metabolic and physiological measures after 12 months of NMN administration in C57BL/6N mice.
Changes in mouse physiological measures do not establish longer human lifespan or cognitive benefit. This experiment cannot provide a safe human anti-aging protocol.
Source 3 · Abstract read
Systematic review / meta-analysis
Yang et al. (2026) included 15 trials, with 10 contributing to safety analyses; follow-up ranged from 14 days to 24 weeks. No clear adverse-event increase was found; significant broad benefits in weight, fasting glucose, HbA1c or lipids were not demonstrated.
The review covers NMN or NMN-related preparations; short follow-up cannot establish rare harms, cancer outcomes or long-term safety. Muscle/blood findings are not cognition or lifespan outcomes; dose ranges are not personal prescriptions or safe upper limits.
Source 5 · Abstract read
Regulatory scientific assessment
The FDA’s general supplement guidance explains that supplements are not approved for safety and effectiveness before sale as drugs are. A supplement label does not mean NMN is approved for cognitive effects or anti-aging treatment.
This guidance alone does not establish NMN’s current product- and country-specific legal classification. Regulatory classification, clinical benefit and drug authorization are separate matters; official product records require separate verification.
Source 6 · Official summary read
2026-11-11 correction: Muscle and blood biomarkers were separated from brain benefit and lifespan; the 2026 review was added. Single-dose tolerability was not extrapolated to long-term safety. Unsupported general half-life, personal-protocol and regulatory-approval inferences were removed.
What is NMN?
NMN is an NAD+ precursor. Small human trials have explored metabolic outcomes; extending human lifespan or improving cognition has not been established.
NMN contributes to NAD+ synthesis through NMNAT. This biochemical pathway does not show that supplementation increases ATP, DNA repair or cognitive performance in the human brain. Cellular and animal findings involving sirtuins and PARP must be distinguished from evidence of slower human aging.
Clinical Evidence
Yoshino et al. (2021) studied 250 mg/day NMN or placebo for 10 weeks in 25 postmenopausal women with prediabetes and overweight/obesity. Muscle insulin sensitivity improved; muscle NAD+ content did not increase and many other metabolic measures were unchanged. Cognition, dementia prevention and lifespan were not evaluated.
Muscle insulin sensitivity in a selected group of women with prediabetes is not general metabolic improvement in healthy people or increased brain NAD+. Tissue measurements, cognition, dementia prevention and lifespan are distinct outcomes.
Irie et al. (2020) studied single doses of 100, 250 and 500 mg NMN in 10 healthy men over 5 hours. Nicotinamide metabolites rose; this trial did not demonstrate blood NAD+ increases or long-term anti-aging effects.
This single-arm, nonrandomized experiment followed 10 men for 5 hours. Increased metabolites do not establish NMN plasma half-life or long-term safety; increased blood NAD+, slower aging and personal doses cannot be inferred.
Mills et al. (2016) reported improvements in selected age-associated metabolic and physiological measures after 12 months of NMN administration in C57BL/6N mice.
Changes in mouse physiological measures do not establish longer human lifespan or cognitive benefit. This experiment cannot provide a safe human anti-aging protocol.
Yang et al. (2026) included 15 trials, with 10 contributing to safety analyses; follow-up ranged from 14 days to 24 weeks. No clear adverse-event increase was found; significant broad benefits in weight, fasting glucose, HbA1c or lipids were not demonstrated.
The review covers NMN or NMN-related preparations; short follow-up cannot establish rare harms, cancer outcomes or long-term safety. Muscle/blood findings are not cognition or lifespan outcomes; dose ranges are not personal prescriptions or safe upper limits.
Dose information and research limits
Dose information and research limits
This dose information describes research or product context; it is not a personal prescription, established safe upper limit or efficacy guarantee for healthy people. Extracts and different formulations should not be treated as equivalent milligram for milligram.
Safety and Side Effects
No clear harm increase in short, small NMN studies does not establish long-term, pregnancy/breastfeeding or drug-combination safety. Missing interaction records are not evidence of safety; do not change cancer treatment or prescribed medicines on your own.
The FDA’s general supplement guidance explains that supplements are not approved for safety and effectiveness before sale as drugs are. A supplement label does not mean NMN is approved for cognitive effects or anti-aging treatment.
This guidance alone does not establish NMN’s current product- and country-specific legal classification. Regulatory classification, clinical benefit and drug authorization are separate matters; official product records require separate verification.
Related research and reading
These links show explicit editorial topic connections; they do not confirm a mechanism, efficacy or the safety of combined use. News dates refer to the source or event.
Educational guides
- Brain Aging: Limits of Nootropic Research
NMN, resveratrol and other compounds are studied for aging mechanisms; no nootropic protocol has been established to slow cognitive decline in humans.
- Mitochondria and Brain Energy: Mechanisms and Evidence
Explore CoQ10, PQQ, NMN and creatine research; mitochondrial mechanisms do not explain every cause of brain fog or guarantee supplement benefits.
Sources
- Yoshino M, et al. (2021). Nicotinamide mononucleotide increases muscle insulin sensitivity in prediabetic women. Science, 372(6547), 1224–1229. PubMed · PMID 33888596
- Irie J, et al. (2020). Effect of oral administration of nicotinamide mononucleotide on clinical parameters and nicotinamide metabolite levels in healthy Japanese men. Endocrine Journal, 67(2), 153–160. PubMed · PMID 31685720
- Mills KF, et al. (2016). Long-term administration of nicotinamide mononucleotide mitigates age-associated physiological decline in mice. Cell Metabolism, 24(6), 795–806. PubMed · PMID 28068222
- Liao B, et al. (2021). Nicotinamide mononucleotide supplementation enhances aerobic capacity in amateur runners: a randomized, double-blind study. Journal of the International Society of Sports Nutrition, 18(1), 54. PubMed · PMID 34238308
- Yang W, et al. (2026). Safety and Metabolism-Related Outcomes of Oral Nicotinamide Mononucleotide Supplementation in Adults: A Systematic Review and Meta-Analysis. Nutrients, 18(14), 2251. https://doi.org/10.3390/nu18142251 PubMed · PMID 42514320
- US Food and Drug Administration. FDA 101: Dietary Supplements. https://www.fda.gov/consumers/consumer-updates/fda-101-dietary-supplements US Food and Drug Administration
Link verification checks the identity of the publication; it does not constitute independent expert review of clinical claims. Our evidence and source methodology · Source directory
Frequently Asked Questions
NMN is an NAD+ precursor. Small human trials have explored metabolic outcomes; extending human lifespan or improving cognition has not been established.
This dose information describes research or product context; it is not a personal prescription, established safe upper limit or efficacy guarantee for healthy people. Extracts and different formulations should not be treated as equivalent milligram for milligram.
No clear harm increase in short, small NMN studies does not establish long-term, pregnancy/breastfeeding or drug-combination safety. Missing interaction records are not evidence of safety; do not change cancer treatment or prescribed medicines on your own.
Sale and import status in Türkiye must be checked for the specific product. Verify supplement approval in the Ministry of Agriculture and Forestry GGBS list, and medicine authorization and conditions of use in TİTCK records. Online availability does not establish approval or unrestricted personal import; current Ministry of Trade conditions apply to postal and express shipments.
No established timeframe